Results 151 to 160 of about 220,949 (359)

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman   +2 more
wiley   +1 more source

Prognostic value of lupus anticoagulant and anti‐β2 glycoprotein I antibody in adverse pregnancy outcomes.

open access: yesArthritis &Rheumatology, Accepted Article.
Objective International criteria for antiphospholipid syndrome (APS) include lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin (Ig) G and IgM, and anti‐β2‐glycoprotein I (β2GPI) IgG and IgM. However, evidence supporting their prognostic value or treatment efficacy in improving live birth rates is limited.
Megumi Nonobe   +8 more
wiley   +1 more source

Development of High-Throughput Multiplex Serology to Detect Serum Antibodies against Coxiella burnetii [PDF]

open access: gold, 2021
Rima Jeske   +6 more
openalex   +1 more source

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen   +14 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

open access: yesArthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

HIVGenoPipe: a nextflow pipeline for the detection of HIV-1 drug resistance using a real-time sample-specific reference sequence

open access: yesBMC Bioinformatics
Background The emergence of HIV drug resistance is a challenge in controlling the acquired immunodeficiency syndrome (AIDS) pandemic caused by human immunodeficiency virus-1 (HIV-1) infection.
Thoai Dotrang   +10 more
doaj   +1 more source

The efficacy of Telitacicept in Childhood‐onset Systemic Lupus Erythematosus: a prospective multi‐center cohort study with IPTW‐adjusted comparison to a historical control group treated with Belimumab

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The therapeutic effects of Telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with Belimumab combined with SoC. Methods We performed a prospective cohort study across 7 tertiary hospitals in China, enrolling patients ...
Chong Luo   +15 more
wiley   +1 more source

serology

open access: yes
Citation: 'serology' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13672 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +2 more sources

Home - About - Disclaimer - Privacy